皮下植入式心律转复除颤器植入时的除颤测试:HONEST研究长期结果
HONEST研究为法国全国性观察性队列,纳入2012—2019年全部接受S-ICD的患者共4,924例,其中82.6%实施除颤测试(DT)。经倾向评分加权分析,未实施DT与全因死亡、心血管死亡、心源性猝死及恰当/不恰当放电风险升高无关,提示多数S-ICD受者可不做DT,高危亚组可考虑选择性DT。
要点
- DT实施率从2012—2014年的85.4%降至2019年的66.9%(P < 0.001)。
- DT失败率1.0%,其中87.8%接受纠正性再干预;DT相关并发症0.1%,含2例死亡。
- 未做DT与全因死亡、心血管死亡、心源性猝死及恰当/不恰当放电风险升高无关。
核心结论
- 在多数S-ICD受者中可安全省略除颤测试(DT),而高危亚组可考虑选择性DT。
研究设计与样本
- HONEST研究为法国全国性、正在进行的观察性研究,纳入2012—2019年全部S-ICD受者,共4,924例。
- 5年终点由中心裁定,并按DT状态进行倾向评分加权分析比较结局。
主要发现
- 4,924例中4,066例(82.6%)实施DT,实施率从2012—2014年的85.4%降至2019年的66.9%(P < 0.001)。
- 未测试患者更年长(51.2 vs 49.6岁;P = 0.007)、左心室射血分数更低(37.6% vs 43.3%;P < 0.001),且更多因一级预防(68.0% vs 62.4%;P = 0.002)和结构性心脏病(84.9% vs 76.8%;P < 0.001)植入。
- DT相关并发症发生率0.1%,包括2例死亡;DT失败率1.0%,其中87.8%接受纠正性再干预。
- DT失败的独立预测因素为高除颤阻抗(≥89 Ω;OR: 4.60;95% CI: 2.32-9.66;P < 0.001)和肥胖(BMI ≥30 kg/m2;OR: 2.17;95% CI: 1.01-4.55;P = 0.007)。
- 校正后,省略DT与全因死亡(HR: 1.17;95% CI: 0.86-1.61;P = 0.313)、心血管死亡(HR: 1.04;95% CI: 0.70-1.56;P = 0.846)、心源性猝死(HR: 0.27;95% CI: 0.04-1.72;P = 0.167)、恰当放电(HR: 1.01;95% CI: 0.78-1.30;P = 0.945)及不恰当放电(HR: 0.98;95% CI: 0.78-1.23;P = 0.865)风险升高无关;无效放电或未检测到室性心律失常的合并发生率相似(0.05 vs 0.06/100人年)。
临床怎么用
- 多数S-ICD受者植入时可考虑省略DT,尤其无高除颤阻抗或肥胖等风险因素者。
- 对除颤阻抗≥89 Ω或BMI ≥30 kg/m2等高危患者,可考虑选择性实施DT。
局限性
- 本研究为观察性研究,DT分组非随机,尽管采用倾向评分加权仍可能存在残余混杂。
- 原文摘要未报告除DT失败预测因素外的其他独立预测因素及亚组分析细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Defibrillation testing (DT) remains recommended during subcutaneous implantable cardioverter defibrillator (S-ICD) implantation due to limited supporting evidence. OBJECTIVES: The objective of this study was to evaluate the long-term impact of DT during S-ICD implantation. METHODS: The HONEST (coHOrte fraNcaise des dEfibrillateurs Sous cuTanés) study is a nationwide, ongoing observational study, including all S-ICD recipients in France (2012-2019). Five-year endpoints were centrally adjudicated, and propensity score-weighted analyses compared outcomes by DT status. RESULTS: Among 4,924 patients, DT was performed in 4,066 (82.6%), decreasing from 85.4% (2012-2014) to 66.9% in 2019 (P < 0.001). Nontested patients were older (51.2 vs 49.6 years; P = 0.007), had lower left ventricular ejection fraction (37.6% vs 43.3%; P < 0.001), and were more frequently implanted for primary prevention (68.0% vs 62.4%; P = 0.002) and structural heart disease (84.9% vs 76.8%; P < 0.001). DT-related complications occurred in 0.1%, including 2 deaths. Failure rate was 1.0%, with 87.8% undergoing corrective reinterventions. Independent predictors of DT failure were elevated shock impedance (≥89 Ω; OR: 4.60; 95% CI: 2.32-9.66; P < 0.001) and obesity (body mass index ≥30 kg/m2; OR: 2.17; 95% CI: 1.01-4.55; P = 0.007). After adjustment, DT omission was not associated with increased risks of overall mortality (HR: 1.17; 95% CI: 0.86-1.61; P = 0.313), cardiovascular mortality (HR: 1.04; 95% CI: 0.70-1.56; P = 0.846), sudden cardiac death (HR: 0.27; 95% CI: 0.04-1.72; P = 0.167), and appropriate (HR: 1.01; 95% CI: 0.78-1.30; P = 0.945) or inappropriate shocks (HR: 0.98; 95% CI: 0.78-1.23; P = 0.865). Combined rates of ineffective shocks or undetected ventricular arrhythmias were similar (0.05 vs 0.06 per 100 person-years). CONCLUSIONS: Our findings suggest that DT can be safely omitted in the majority of S-ICD recipients, whereas selective DT may be considered in higher-risk subgroups. (S-ICD French Cohort Study (HONEST); NCT05302115).
引用
- Kerkouri F, Eschalier R, Fareh S, et al. Defibrillation Testing During Implantation of Subcutaneous Implantable Cardioverter Defibrillators. J Am Coll Cardiol. 2025. PMID: 40602942. doi:10.1016/j.jacc.2025.04.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。